Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Bayer to cut 950 jobs in Berlin following Schering takeover
- LEVERKUSEN, Germany AFP — German chemicals and pharmaceutcials giant Bayer said Wednesday that it planned to axe 950 jobs in Berlin following its acquisition of drug-maker Schering, which is based in the German capital. Schering employs a workforce of about 5,500 in Berlin. The cuts, which would not...
- Research articles 2007-02-28
- Schering-Plough Now in the Feds' Crosshairs
- Schering-Plough Now in the Feds' CrosshairsThe Great Disappointment of EthicsPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and...
- Discussion threads 2008-07-10
- Is Merck Hanging Schering Out to Dry on Vytorin?
- Is Merck Hanging Schering Out to Dry on Vytorin?VytorinPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and Merck...
- Discussion threads 2008-07-07
- Bayer to axe 1,000 jobs at Schering
- BERLIN AFP — Bayer, the German chemicals and pharmaceuticals specialist, plans to axe 1,000 jobs at its Berlin-based drug maker Schering, the daily Der Tagesspiegel reported in an advance copy of its Monday issue. The company was to inform its Berlin staff on March 2 about the job cuts,...
- Research articles 2007-02-18
- How Pharma Stacks the Deck with Medical Journals
- How Pharma Stacks the Deck with Medical JournalsStatistical GymnasticsPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and Merck...
- Discussion threads 2008-06-18
- Global Pharmacology Expert Joins PhytoMedical
- Dr. Jay R. Wiggins, Accomplished Pharmaceutical Researcher with European and North American Drug Discovery and Development Expertise, Joins PhytoMedical Scientific Advisory Board PRINCETON, N.J. -- PhytoMedical Technologies, Inc. (OTCBB:PYTO) (FWB:ET6) announced today the addition of pharmacology researcher and drug discovery and development expert, Dr. Jay R. Wiggins, to the...
- Research articles 2006-10-11
- Postbank to replace Schering in German blue-chip DAX stock index
- FRANKFURT AFP — Postbank, the banking arm of German postal and logistics giant Deutsche Post, is to replace pharmaceuticals specialist Schering in the Frankfurt stock exchange's blue-chip DAX 30 stock index, stock market operator Deutsche Boerse announced. The switch would take place on September 18, Deutsche Boerse said in a...
- Research articles 2006-09-06
- Marketing Trumps Science in Vytorin Scandal
- In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year. ...
- Blog posts 2008-04-01
- Schering net profit up in first quarter
- BERLIN AFP — Schering, the German pharmaceuticals specialist, has said that strong demand for its best-selling multiple sclerosis drug Betaferon and its Yasmin contraceptive pill boosted earnings in the first three months of the current year. Schering, currently being taken over by bigger rival Bayer, said in a statement...
- Research articles 2006-04-19
- Schering boss welcomes takeover, regrets loss of independence
- BERLIN AFP — German pharmaceutical group Bayer's purchase of rival Schering makes sense commercially and strategically, Schering boss Hubertus Erlen said in an interview, while regretting his company's loss of independence. Bayer announced a cash offer for Schering of 86.0 euros (103 dollars) per share late on Thursday, presenting...
- Research articles 2006-03-25
- Schering raises profit targets after robust third quarter
- BERLIN AFP — German drug maker Schering said it was raising its full-year profit targets after third-quarter earnings beat expectations. "Based on the outstanding performance of our business, we are raising our profitability goal and now expect the operating margin for 2005 to be above 17 percent," Schering chairman...
- Research articles 2005-10-24
- Schering stops testing of new uterus drug
- BERLIN AFP — German drug maker Schering said that it had stopped testing of its new drug Asoprisnil, a treatment for uterine fibroids, after some patients had experienced adverse side-effects in late-stage clinical trials. The announcement depressed shares in Schering as it raised questions over the launch of yet...
- Research articles 2005-10-12
- Schering's menopause drug Angeliq approved for marketing in US
- BERLIN AFP — Schering said that its menopause treatment Angeliq had finally been approved for launch in the United States. "The US Food and Drug Administration FDA has approved Angeliq to treat moderate to severe menopausal symptoms," Schering said in a statement. While the drug is already available...
- Research articles 2005-09-29
- Schering raises 2005 outlook after better-than-expected second quarter
- BERLIN AFP — Schering, the German pharmaceuticals group, is raising its full-year forecasts after a better-than-expected second quarter and a strong first six months. Schering, the world's leading maker of contraceptives and fertility drugs, said in a statement that net profit had risen by 34 percent to 176 million...
- Research articles 2005-07-22
- Drugmakers go furthest to sway Congress
- Correction ran 4/29/05: A story Tuesday about lobbying by the pharmaceutical industry noted an incorrect affiliation for David Fassler, a witness at a Senate hearing. Fassler was representing the American Psychiatric Association. WASHINGTON -- When Sen. Bill Frist needed help in November for a quick tour celebrating the victories...
- Research articles 2005-04-26
- AIG unit hit with bad-faith charges; Schering-Plough, Lexington disagree over interpretation of liability policy wording.(News)(American International Group Inc.)
- Byline: DOUGLAS McLEOD NEWARK, N.J.-Pharmaceutical giant Schering-Plough Corp. is leveling bad-faith charges against an American International Group Inc. unit for its alleged refusal to pay more than $21 million in product liability losses on thre Byline: DOUGLAS McLEOD NEWARK, N.J.-Pharmaceutical...
- Research articles 2005-08-08
- Industrial Research Institute's 6th annual R&D leaderboard: R&D spending by the top 100 U.S. and global technology investors in 2003
- Neither IRI's nor other industry sages' predictions or early estimates for R&D spending in 2003 foresaw the robust turnaround in R&D that actually occurred. Spending in 2003 by the top 100 U.S. companies increased from 2002 by 5.4 percent to $120 billion (Table 1). In retrospect, with better data now...
- Research articles 2004-11-01
- FTC rules against Schering.(Behind The Lines)(Brief Article)
- THE U.S. FEDERAL TRADE COMMISSION ruled in December that Schering-Plough Corporation, Upsher-Smith Laboratories, and American Home Products AHP entered into illegal agreements in 1997 and 1998 to delay the entry of lower-cost generic competition for Schering's prescription drug K-Dur 20, which is used to treat people...
- Research articles 2003-12-01
- Berlex Laboratories Believes Drug Invented at Immunex Has Great Potential.
- By Luke Timmerman, The Seattle Times Knight Ridder/Tribune Business News Jan. 15--Dr. Mark Gilbert and his colleagues have careers staked on Leukine, the first drug to emerge from Seattle biotechnology, a product that many believe has never reached its full potential. ...
- Research articles 2003-01-15
- Late News.
- Starting `afresh,' United breaks new ads [elk grove village, ill.] United Airlines, after a labor pact that averted a mechanics' strike, launches a TV and print campaign March 12 with a heavy run during CBS' NCAA basketball tournament telecasts. The effort features United employees...
- Research articles 2002-03-11
- << Previous
- page 1 of 3
- Next >>
Refining Tags
- Schering-Plough Corp. (13 results)
- Merck & Co. Inc. (12 results)
- Finance (11 results)
- Jim Edwards (11 results)
- Agence France-Presse (9 results)
- Marketing (8 results)
- Investment (7 results)
- Bayer AG (7 results)
- Vytorin (6 results)
- Sales (6 results)
- David P. Hamilton (5 results)
- Mergers & Acquisitions (5 results)
- FDA (5 results)
- FTC (4 results)
- Agreement (4 results)
- Sales Strategy (4 results)
- Johnson & Johnson (4 results)
- Berlin (4 results)
- Business Operations (4 results)
- Stock (4 results)
- Human Resources (3 results)
- Merger (3 results)
- Strategy (3 results)
- Marketing Research (3 results)
- ENHANCE Trial (3 results)
- Zocor (3 results)
- Revenue (3 results)
- Aventis (3 results)
